Preview

Онкогематология

Расширенный поиск

Экстранодальная NK/Т-клеточная лимфома: обзор литературы, описание клинического случая

https://doi.org/10.17650/1818-8346-2016-11-3-29-39

Полный текст:

Аннотация

Экстранодальная NK/Т-клеточная лимфома – редкое лимфопролиферативное заболевание, характеризующееся преимущественно экстранодальной локализацией, агрессивным течением и низкой эффективностью стандартной химиотерапии. Клиническая картина разнообразна и зависит от локализации очага опухолевого поражения. В статье мы представили обзор литературы и описали случай генерализованной экстранодальной NK/Т-клеточной лимфомы, протекающей с поражением костного мозга, необычной интракраниальной локализацией одного из опухолевых очагов, лейкемизацией опухолевого процесса и нейролейкемией.
Правильно выбранная тактика лечения позволила достигнуть продолжительной полной ремиссии у пациента из группы неблагоприятного прогноза.

Об авторах

Н. Г. Чернова
ФГБУ «Гематологический научный центр» Минздрава России
Россия


М. В. Нарейко
ФГБУ «Гематологический научный центр» Минздрава России
Россия


М. Н. Синицына
ФГБУ «Гематологический научный центр» Минздрава России
Россия


Ю. В. Сидорова
ФГБУ «Гематологический научный центр» Минздрава России
Россия


Г. А. Яцык
ФГБУ «Гематологический научный центр» Минздрава России
Россия


А. М. Ковригина
ФГБУ «Гематологический научный центр» Минздрава России
Россия


Е. Е. Звонков
ФГБУ «Гематологический научный центр» Минздрава России
Россия


В. Н. Двирнык
ФГБУ «Гематологический научный центр» Минздрава России
Россия


Л. А. Кузьмина
ФГБУ «Гематологический научный центр» Минздрава России
Россия


Е. Н. Паровичникова
ФГБУ «Гематологический научный центр» Минздрава России
Россия


В. Г. Савченко
ФГБУ «Гематологический научный центр» Минздрава России
Россия


Список литературы

1. Swerdlow S. H., Campo E., Harris N. L. et al. WHO classification of tumor of haemato poietic and lymphoid tissues. Lyon: IARC, 2008. P. 285–288.

2. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;1;26(25):4124–30. DOI: 10.1200/JCO.2008.16.4558.

3. Виноградова Ю. Е., Зингерман Б. В. Нозологические формы и выживаемость пациентов с Т- и НК-клеточными лимфатическими опухолями, наблюдающихся в ГНЦ в течение 10 лет. Клиническая онкогематология, Фундаментальные исследования и клиническая практика 2011;4(3):201–12. [Vinogradova Yu. E., Zingerman B. V. Nosology and survival of patients with T- and NK-cell lymphatic tumors observed in the Hematological Research Center during 10 years. Klinicheskaya onkogematologiya: Fundamental’nye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Basic Research and Clinical Practice 2011;4(3):201–12. (In Russ.)].

4. T-cell lymphomas (Contemporary Hematology). Ed. by Francine Foss. Humana Press, 2013. P. 25. DOI: 10.1007/978-1-62703-170-7.

5. Anderson J. R., Armitage J. O., Weisenburger D. D. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 1998;9(7):717–20. PMID: 9739436.

6. Au W. Y., Weisenburger D. D., Intragumtornchai T., Nakamura S. et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;23;113(17):3931–7. DOI: 10.1182/blood-2008-10-185256.

7. Kim T. M., Lee S. Y., Jeon Y. K. et al. Clinical heterogeneity of extranodal NK/Tcell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 2008;19(8):1477–84. DOI: 10.1093/annonc/mdn147.

8. Mohapatra A., Viswabandya A., Samuel R. et al. T. NK/T-cell lymphoma in a renal transplant recipient and review of literature. Indian J Nephrol 2011;21(1):44–7. DOI: 10.4103/0971–4065.78078.

9. Hsi E. D., Picken M. M., Alkan S. Post-transplantation lymphoproliferative disorder of the NK-cell type: a case report and review of the literature. Mod Pathol 1998;11(5):479–84. PMID: 9619602.

10. Tse E., Leung R., Khong P. L. et al. Non-nasal natural killer cell lymphoma: not non-nasal after all. Ann Hematol 2009;88(2):185–7. DOI: 10.1007/s00277-008-0562-0.

11. Han A. R., Lee H. R., Park B. B. et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol 2007;86(7):493–8. PMID: 17347847.

12. Han L., Li L., Wu J. et al. Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome. Leuk Lymphoma 2014;55(9):2048–55. DOI: 10.3109/10428194.2013.876629.

13. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987–94. PMID: 8141877.

14. Rosenberg S. A., Boiron M., DeVita V. T. Jr. et al. Report of the Committee on Hodgkin’s Disease Staging Procedures. Cancer Res 1971;31(11):1862–3. PMID: 5121695.

15. Tong H., Ren Y., Qian W. et al. Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. Int J Hematol 2009;90(3):303–10. DOI: 10.1007/s12185-009-0390-6.

16. Kato S., Takahashi E., Asano N., et al. Nodal cytotoxic molecule (CM) – positive Epstein-Barr virus (EBV) – associated peripheral T cell lymphoma (PTCL): a clinicopathological study of 26 cases. Histopathology 2012;61(2):186–99. DOI: 10.1111/j.1365–2559.2012.04199.x.

17. Yamaguchi M., Ohno T., Oka K. et al. Discordant reaction of Leu4 and rabbit antihuman CD3 epsilon in sinonasal “T”-cell lymphoma. Int J Hematol 1993;59(1):25–30. PMID: 8161733.

18. Emile J. F., Boulland M. L., Haioun C. et al. CD5–CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 1996;87(4):1466–73. PMID: 8608237.

19. Ng S. B., Lai K. W., Murugaya S. et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol 2004;17(9):1097–107. DOI: 10.1038/modpathol.3800157.

20. Wong K. F., Zhang Y. M., Chan J. K. Cytogenetic abnormalities in natural killer cell lymphoma/leukaemia – is there a consistent pattern? Leuk Lymphoma 1999;34(3–4):241–50. DOI: 10.3109/10428199909050949.

21. Shen L., Liang A. C., Lu L. et al. Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma. Am J Pathol 2002;161(6):2123–31. DOI: 10.1016/S0002–9440(10)64490–2.

22. Takahara M., Kishibe K., Bandoh N. et al. P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum Pathol 2004;35(1):86–95. PMID: 14745729.

23. Kim T. M., Park Y. H., Lee S. Y. et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005;106(12):3785–90. DOI: 10.1182/blood-2005-05-2056.

24. Chim C. S., Ma S. Y., Au W. Y. et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004;103(1):216–21. DOI: 10.1182/blood-2003-05-1401.

25. Lee J., Suh C., Park Y. H. et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24(4):612–8. PMID: 16380410.

26. Kim S. J., Kim K., Kim B. S. et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009;27(35):6027–32. DOI: 10.1200/JCO.2009.23.8592.

27. Yamaguchi M., Tobinai K., Oguchi M. et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009;27(33):5594–600. DOI: 10.1200/JCO.2009.23.8295.

28. Hong M., Lee T., Young Kang S. et al. Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior. Mod Pathol 2016;29(5):430–43. DOI: 10.1038/modpathol.2016.47.

29. Huang W. T., Chang K. C., Huang G. C. et al. Bone marrow that is positive for Epstein–Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica 2005;90(8):1063–9. PMID: 16079105.

30. Lei K. I., Chan L. Y., Chan W. Y. et al. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 2002;8(1):29–34. PMID: 11801537.

31. Suzuki R., Yamaguchi M., Izutsu K. et al. NK-cell Tumor Study Group. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 2011;118(23):6018–22. DOI: 10.1182/blood-2011-05-354142.

32. Yan Z., Huang H. Q., Wang X. X. et al. A TNM Staging System for Nasal NK/T-Cell Lymphoma. PLoS One 2015;10(6):e0130984. DOI: 10.1371/journal.pone.0130984.

33. Kim G. E., Cho J. H., Yang W. I. et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000;18(1):54–63. PMID: 10623693.

34. Li Y. X., Yao B., Jin J. et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24(1):181–9. PMID: 16382127.

35. Koom W. S., Chung E. J., Yang W. I. et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004;59(4):1127–37. DOI: 10.1016/j. ijrobp.2003.12.006.

36. Cheung M. M., Chan J. K., Lau W. H. et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54(1):182–90. PMID: 12182990.

37. Li C. C., Tien H. F., Tang J. L. et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004;100(2):366–75. DOI: 10.1002/cncr.11908.

38. Drйnou B., Lamy T., Amiot L. et al. CD3–CD56+ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood 1997;89(8):2966–74. PMID: 9108417.

39. Huang H., Lin Z., Lin X. et al. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leuk Lymphoma 2011;52(6):1041–8. DOI: 10.3109/10428194.2011.561388.

40. Okamoto M., Maruyama F., Tsuzuki M. et al. Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin’s lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki 1994;35(7):635–41. PMID: 8065017.

41. Avilйs A., Cleto S., Castaсeda C., Nambo M. J. CMED in the treatment of nasalnatural killer cell lymphoma with distant metastases. Hematology 2007;12(3):241–4. DOI: 10.1080/10245330701214327.

42. Yamaguchi M., Kwong Y. L. Kim W. S. et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29(33): 4410–6. DOI: 10.1200/JCO.2011.35.6287.

43. Kwong Y. L., Kim W. S., Lim S. T. et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012;120(15):2973–80. DOI: 10.1182/blood-2012-05-431460.

44. Wang J. H., Wang L., Liu C. C. et al. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma. Oncotarget 2016 Apr 8. DOI: 10.18632/oncotarget.8647.

45. Dong L. H., Zhang L. J., Wang W. J. et al. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma. Leuk Lymphoma 2016;57(7):1600–6. DOI: 10.3109/10428194.2015.1108415.

46. Kim S. J., Park S., Kang E. S. et al. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. Ann Hematol 2015;94(1):71–8. DOI: 10.1007/s00277-014-2171-4.

47. Yokoyama H., Yamamoto J., Tohmiya Y. et al. Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type. Leuk Lymphoma 2010; 51(8):1509–12. DOI: 10.3109/10428194.2010.487958.

48. Li M., Gao C., Li H. et al. Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK/T-cell lymphoma. Med Oncol 2011;28(3):840–5. DOI: 10.1007/s12032-010-9532-1.

49. Чумаков П. Л. Клиническое наблюдение NK/Т-клеточной лимфомы назального типа. Российская оториноларингология 2014;1:225–31. [Chumakov P. L. Case of nasal type NK/T-cell lymphoma. Rossiyskaya otorinolaringologiya = Russian Otorhino laryngolog 2014;1:225–31. (In Russ.)].

50. Мустафаев Д. М., Свистушкин В. М., Цагадаева С. Б., Карпова А. Н. Т-клеточная лимфома назального типа. Вестник оториноларингологии 2010;6:70–2. [Mustafaev D. M., Svistushkin V. M., Tsagadaeva S. B., Karpova A. N. Nasal type T-cell lymphoma. Vestnik otorinolaringologii = Bulletin of otorhinolaryngolog 2010;6:70–2. (In Russ.)].

51. Ozaki S., Funasaka Y., Tsuruta K. et al. Extranodal natural killer/T-cell lymphoma, nasal type, presenting with altered CD56 expression: A case report. J Dermatol 2015;42(10):1022–3. DOI: 10.1111/1346–8138.13018.

52. Christopoulos P., Bertz H., Ihorst G. et al. Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hemato logic malignancies necessitating enhanced central nervous system activity. Biol Blood Marrow Transplant 2012;18(9): 1430–7. DOI: 10.1016/j.bbmt.2012.02.016.


Для цитирования:


Чернова Н.Г., Нарейко М.В., Синицына М.Н., Сидорова Ю.В., Яцык Г.А., Ковригина А.М., Звонков Е.Е., Двирнык В.Н., Кузьмина Л.А., Паровичникова Е.Н., Савченко В.Г. Экстранодальная NK/Т-клеточная лимфома: обзор литературы, описание клинического случая. Онкогематология. 2016;11(3):29-39. https://doi.org/10.17650/1818-8346-2016-11-3-29-39

For citation:


Chernova N.G., Nareyko M.V., Sinitsyna M.N., Sidorova Y.V., Yatsy G.A., Kovrigina A.M., Zvonkov E.E., Dvirnyk V.N., Kuz’mina L.A., Parovichnikova E.N., Savchenko V.G. Extranodal NK/T-cell lymphoma: a review of literature and case report. Oncohematology. 2016;11(3):29-39. (In Russ.) https://doi.org/10.17650/1818-8346-2016-11-3-29-39

Просмотров: 573


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1818-8346 (Print)
ISSN 2413-4023 (Online)